公开(公告)号：US20190060624A1

公开(公告)日：2019-02-28

申请号：US16036650

申请日：2018-07-16

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61M31/00 ,  A61K38/28 ,  A61K9/48 ,  A61K31/155 ,  A61M5/20 ,  A61M5/172 ,  A61M5/168 ,  A61K45/06 ,  A61K38/29 ,  A61K9/00 ,  A61K38/27 ,  A61K38/26 ,  A61K38/22 ,  A61K38/17 ,  A61M5/142 ,  A61M5/14

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US10202434B2

公开(公告)日：2019-02-12

申请号：US15387817

申请日：2016-12-22

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS

发明人： Robert C. Gensure ,  Joshua Sakon ,  Osamu Matsushita ,  Tulasi Ponnapakkam

IPC分类号： A61K38/29 ,  C07K14/635 ,  C12N9/52 ,  C12N9/64 ,  A61K8/64 ,  A61K8/66 ,  A61K38/48 ,  A61Q7/00 ,  C12N9/50 ,  A61K38/16 ,  A61K35/28 ,  A61K9/00 ,  C12N9/10

摘要： Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

公开(公告)号：US10130686B2

公开(公告)日：2018-11-20

申请号：US15357818

申请日：2016-11-21

申请人： NANOPHARMACEUTICALS LLC

发明人： Shaker A. Mousa ,  Paul J. Davis

IPC分类号： A61K9/16 ,  A61K38/29 ,  A61K31/192 ,  A61K31/4412 ,  A61K45/06 ,  A61K9/50 ,  A61K9/51 ,  A61K31/05 ,  A61K31/573 ,  A61K31/60 ,  A61K31/675 ,  A61K47/60 ,  A61K47/58 ,  A61K47/59 ,  A61K47/61 ,  A61K47/64

摘要： Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.

公开(公告)号：US20180325994A1

公开(公告)日：2018-11-15

申请号：US16044211

申请日：2018-07-24

申请人： AEGIS THERAPEUTICS, LLC

发明人： Edward T. Maggio

IPC分类号： A61K38/12 ,  A61K47/26 ,  A61K31/70 ,  A61K31/4439 ,  A61K9/00 ,  A61K38/29 ,  A61K9/08 ,  A01N43/16 ,  A01N33/08 ,  A61K47/18

CPC分类号： A61K38/12 ,  A01N33/08 ,  A01N43/16 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4439 ,  A61K31/70 ,  A61K38/29 ,  A61K47/183 ,  A61K47/26 ,  Y02A50/473

摘要： Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 in preventing growth of specified bacteria and fungi.

公开(公告)号：US20180318429A1

公开(公告)日：2018-11-08

申请号：US16032952

申请日：2018-07-11

申请人： Rezolute, Inc.

发明人： Mary S. Rosendahl ,  Sankaram B. Mantripragada ,  Eliana B. Gomez

IPC分类号： A61K47/60 ,  A61K47/12 ,  A61K38/29 ,  A61K38/28 ,  A61K38/27 ,  A61K38/26 ,  A61K9/00 ,  A61K38/08 ,  A61K31/194 ,  A61K9/50 ,  A61K9/16 ,  A61K38/16

摘要： Examples may include a method of making a protein-PEG conjugate salt with increased hydrophobicity. The method may include providing an aqueous protein solution. This aqueous protein solution may include a protein and a pH buffer. The method may also include reacting a polyethylene glycol with the protein to form a protein-PEG conjugate. The method may further include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid in an organic phase. The protonation may form the protein-PEG conjugate salt having a hydrophobic anion that increases the hydrophobicity-PEG conjugate salt.

公开(公告)号：US20180280481A1

公开(公告)日：2018-10-04

申请号：US15766546

申请日：2016-10-07

申请人： Cyprumed GmbH

发明人： Florian FÖGER ,  Martin WERLE

IPC分类号： A61K38/26 ,  A61K38/29 ,  A61K38/08 ,  A61K45/06 ,  A61K9/48

摘要： The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

公开(公告)号：US20180228913A1

公开(公告)日：2018-08-16

申请号：US15673037

申请日：2017-08-09

申请人： Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) ,  UNIVERSIDAD CATOLICA DE CORDOBA ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)

发明人： David KLATZMANN ,  Eliane PIAGGIO ,  Hugo LUJAN

IPC分类号： A61K47/64 ,  A61K38/26 ,  A61K38/27 ,  A61K38/20 ,  A61K38/29 ,  A61K38/28 ,  A61K47/42 ,  C07K14/44

摘要： The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

公开(公告)号：US10046058B2

公开(公告)日：2018-08-14

申请号：US14954591

申请日：2015-11-30

申请人： AntriaBio, Inc.

发明人： Mary S. Rosendahl ,  Sankaram B. Mantripragada ,  Eliana B. Gomez

IPC分类号： A61K9/16 ,  A61K31/194 ,  A61K38/00 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/48 ,  A61K38/16 ,  A61K38/29 ,  A61K38/08 ,  A61K9/00 ,  A61K47/12 ,  A61K9/50 ,  A61K47/60

摘要： Examples may include a microsphere. The microsphere may include a biodegradable polymer. Furthermore, the microsphere may include a protein mixture selected from the group consisting of a protein-polyethylene glycol conjugate, the protein-polyethylene glycol conjugate and the hydrophobic anion of the organic acid, a protein and the hydrophobic anion of the organic acid, and combinations thereof. Examples may also include a method of making the microspheres. The method may further include reacting a polyethylene glycol with a protein to form a protein-PEG conjugate. In addition, the method may include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid to form the protein-PEG conjugate salt. Furthermore, the method may include mixing the protein-PEG conjugate salt in an organic solvent with a biodegradable polymer. The method may also include emulsifying the mixture. Additionally, the method may include hardening the emulsified mixture into the controlled-release microspheres.

公开(公告)号：US10005817B2

公开(公告)日：2018-06-26

申请号：US14646246

申请日：2013-11-20

申请人： EUMEDERIS PHARMACEUTICALS, INC.

发明人： John J. Nestor

IPC分类号： A61K47/48 ,  C07K7/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/26 ,  A61K38/29 ,  C07K1/107 ,  C07K5/065 ,  C09D101/28 ,  A61K38/00

CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K38/07 ,  A61K38/08 ,  A61K38/26 ,  A61K38/29 ,  C07K1/1077 ,  C07K5/06078 ,  C09D101/28

摘要： Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

公开(公告)号：US20180104462A1

公开(公告)日：2018-04-19

申请号：US15668421

申请日：2017-08-03

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61M31/00 ,  A61K38/29 ,  A61K9/48 ,  A61K31/155 ,  A61K38/17 ,  A61M5/20 ,  A61M5/172 ,  A61M5/168 ,  A61K45/06 ,  A61K9/00 ,  A61K38/28 ,  A61K38/27 ,  A61K38/26 ,  A61K38/22 ,  A61M5/142 ,  A61M5/14

CPC分类号： A61M31/002 ,  A61K9/0065 ,  A61K9/48 ,  A61K9/4808 ,  A61K31/155 ,  A61K38/17 ,  A61K38/22 ,  A61K38/2235 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K38/29 ,  A61K45/06 ,  A61M5/14276 ,  A61M5/168 ,  A61M5/1723 ,  A61M5/20 ,  A61M2005/1401 ,  A61M2005/14284 ,  A61M2230/005 ,  A61K2300/00

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.